These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 17275988)

  • 1. Rebuttal from authors re: Edward M. Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007;51:1477-8.
    Karakiewicz P; Perrotte P; Trinh QD; Patard JJ
    Eur Urol; 2007 Jun; 51(6):1478-80. PubMed ID: 17275988
    [No Abstract]   [Full Text] [Related]  

  • 2. Node positive renal cell cancer. Who can be helped?
    Messing EM
    Eur Urol; 2007 Jun; 51(6):1477-8. PubMed ID: 17240037
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 4. Rebuttal from authors re: Vincenzo Ficarra, Antonio Galfano and Stefano Cavalleri. Is simple enucleation a minimal partial nephrectomy responding to the EAU guidelines' recommendations? Eur Urol 2009;55:1315-8.
    Minervini A; Serni S; Di Cristofano C; Carini M
    Eur Urol; 2009 Jun; 55(6):1319-20. PubMed ID: 18804906
    [No Abstract]   [Full Text] [Related]  

  • 5. Current clinical trials in renal cell carcinoma.
    Sokoloff MH; Daneshmand S; Ryan CW
    Urol Oncol; 2005; 23(4):289-92. PubMed ID: 16018946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Puppo P, Introini C, Calvi P, Naselli A. Long term results of excision of small renal cancer surrounded by a minimal layer of grossly normal parenchyma: review of 94 cases. Eur Urol 2004;46:477-81.
    Carini M; Lapini A; Minervini A; Serni S
    Eur Urol; 2005 Feb; 47(2):265-6; author reply 266. PubMed ID: 15661426
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Steiner T, Knels R, Schubert J. Prognostic significance of tumor size in patients after tumour nephrectomy for localised renal cell carcinoma. Eur Urol 46;2004:327-30.
    Bogdanovic J
    Eur Urol; 2005 Feb; 47(2):266-7. PubMed ID: 15661427
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Harshman LC; Srinivas S
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Ziya Kirkali and Hein van Poppel. A critical analysis of surgery for kidney cancer with vena cava invasion. Eur Urol 2007;52:658-62.
    Labanaris AP; Kühn R; Schott GE; Zugor V
    Eur Urol; 2007 Dec; 52(6):1800-1; author reply 1801-2. PubMed ID: 17888565
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting cancer-control outcomes in patients with renal cell carcinoma.
    Karakiewicz PI; Hutterer GC
    Curr Opin Urol; 2007 Sep; 17(5):295-302. PubMed ID: 17762620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Mesut Remzi, Michael Marberger. Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur urol 2009;55:359-67.
    Park BK
    Eur Urol; 2009 Jun; 55(6):e99-100; author reply e101-2. PubMed ID: 19286305
    [No Abstract]   [Full Text] [Related]  

  • 14. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy: R. H. Breau, P. L. Crispen, R. E. Jimenez, C. M. Lohse, M. L. Blute and B. C. Leibovich J Urol 2010; 183: 903-908.
    Cimen HI; Canda AE; Balbay MD
    J Urol; 2010 Nov; 184(5):2212; author reply 2212-3. PubMed ID: 20864129
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal cell carcinoma: vena caval involvement.
    Boorjian SA; Sengupta S; Blute ML
    BJU Int; 2007 May; 99(5 Pt B):1239-44. PubMed ID: 17441917
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of pathology for clinical decision-making in renal cell carcinoma is increasing.
    Terrone C; Volpe A
    Eur Urol; 2007 May; 51(5):1166-8; discussion 1168-70. PubMed ID: 17257741
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma.
    Margulis V; McDonald M; Tamboli P; Swanson DA; Wood CG
    J Urol; 2009 May; 181(5):2044-51. PubMed ID: 19286220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment.
    Uzzo RG
    J Urol; 2009 Nov; 182(5):2171. PubMed ID: 19758642
    [No Abstract]   [Full Text] [Related]  

  • 20. Lymph node dissection is not obsolete in clinically node-negative renal cell carcinoma patients.
    Van Poppel H
    Eur Urol; 2011 Jan; 59(1):24-5. PubMed ID: 20943309
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.